An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Taysha Gene Therapies to Participate in Upcoming Gene Therapy Summit
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Taysha Gene Therapies, Inc. (NASDAQ: TSHA) will participate in a fireside chat at the Jefferies Gene Therapy & Editing Summit on October 28, 2021, at 11:00 am ET. This pivotal-stage company focuses on developing AAV-based gene therapies for monogenic diseases affecting the central nervous system. Key participants include RA Session II, President and CEO; Dr. Suyash Prasad, Chief Medical Officer; Kamran Alam, CFO; and Dr. Kimberly Lee, SVP of Corporate Communications. Taysha aims to rapidly translate innovative therapies from research to clinical application.
Positive
None.
Negative
None.
Jefferies Gene Therapy & Editing Summit on October 28 at 11:00 am ET
DALLAS--(BUSINESS WIRE)--
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in a fireside chat at the Jefferies Gene Therapy & Editing Summit.
Conference Details:
Event:
Jefferies Gene Therapy & Editing Summit
Date:
Thursday, October 28, 2021
Time:
11:00 am ET
Format:
Fireside Chat
Participants:
RA Session II, President, Founder and Chief Executive Officer
Dr. Suyash Prasad, Chief Medical Officer and Head of R&D
Kamran Alam, Chief Financial Officer
Dr. Kimberly Lee, SVP, Corporate Communications and Investor Relations
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.
What is Taysha Gene Therapies' participation in the Jefferies Summit on October 28, 2021?
Taysha Gene Therapies, Inc. will host a fireside chat at the Jefferies Gene Therapy & Editing Summit on October 28, 2021, at 11:00 am ET.
Who are the key speakers representing Taysha Gene Therapies at the Jefferies Summit?
The key speakers from Taysha Gene Therapies include RA Session II (President & CEO), Dr. Suyash Prasad (Chief Medical Officer), Kamran Alam (CFO), and Dr. Kimberly Lee (SVP, Corporate Communications).
What is the focus of Taysha Gene Therapies' work?
Taysha Gene Therapies focuses on developing and commercializing AAV-based gene therapies for the treatment of central nervous system monogenic diseases.
What is the stock symbol for Taysha Gene Therapies?
The stock symbol for Taysha Gene Therapies is TSHA.
